MSFrontier

Assessing the Potential Ability of GSK239512 to Remyelinate Brain Lesions in Relapsing Remitting Multiple Sclerosis

Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis
CompletedPhase 2Relapsing MS2012-003627-38

What was tested

Treatment tested

  • Gsk239512

    Histamine H3 receptor antagonist

What it measured

Main measures

  • Changes in lesion myelination using two exploratory

    MRI lesions

Other measures (1)

  • Change from baseline in T2 lesion MTR at Week 48. Cumulative new and enlarging Gd enhancing, T2 and Combined Unique Active lesions comparing placebo to GSK239512 treated subjects.

    MRI lesionsMyelin repair

Papers

    Loading reviews and guidelines…

    Related trials

    • ReINFORCE

      Phase 1 / Phase 2 · Not yet recruiting

      Still running

    • VISTA

      Phase 2 · Completed

      No result found

    • CCMR One

      Phase 2 · Completed

      Main goal was not benefit

    • ReBUILD

      Phase 2 · Completed

      Met its main goal

    History

    1. In scope changed from true to false

    1. Started

      Sept 2012

    Assembled by software from public sources and not checked by people. Each record links to its source. Report an error